Mobile

A Randomized Phase 2 Study Comparing Erlotinib-Pemetrexed, Pemetrexed alone, and Erlotinib alone, as Second-Line Treatment for Non-Smoker Patients with Locally Advanced or Metastatic Non-Small Cell Lu...

Mise à jour : Il y a 4 ans
Référence : EUCTR2007-003912-72

A Randomized Phase 2 Study Comparing Erlotinib-Pemetrexed, Pemetrexed alone, and Erlotinib alone, as Second-Line Treatment for Non-Smoker Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To compare an erlotinib-pemetrexed combination with pemetrexed alone, and erlotinib alone, in terms of progression-free survival (PFS) in non-smoker patients with locally advanced or metastatic (Stage IIIA, IIIB, or IV) nonsquamous NSCLC who have failed first-line chemotherapy treatment.

Critère d'inclusion

  • Patients with histological or cytological diagnosis of nonsquamous NSCLC with locally advanced or metastatic disease. Patients must have failed only one prior chemotherapy regimen and must be considered eligible for further chemotherapy following progression of their disease

Liens